Average Insider

Where insiders trade, we follow

Insider Buy/Sell Details for the Biotechnology Industry — Last 3 Months

Extreme outlier transactions (>3σ) are excluded.Show All Data
Ratio0.1:1
Daily Buy & Sell Volume

Spyre Therapeutics, Inc. (SYRE)

Sloan Sheldon — Chief Medical Officer
May 1, 2026
Sale
Shares
21,306
Price
$69.53
Total Value
$1.48M
Shares Held After
57,027
% of Holdings
27.2%
May 1, 2026
Sale
Shares
2,502
Price
$27.17
Total Value
$67.98K
Shares Held After
36,394
% of Holdings
6.4%

Oruka Therapeutics, Inc. (ORKA)

Sandler Laura Lee — Chief Operating Officer
May 1, 2026
Sale
Shares
100
Price
$68.48
Total Value
$6.85K
Shares Held After
236,984
% of Holdings
0.0%

Oruka Therapeutics, Inc. (ORKA)

Sandler Laura Lee — Chief Operating Officer
May 1, 2026
Sale
Shares
200
Price
$67.16
Total Value
$13.43K
Shares Held After
237,084
% of Holdings
0.1%

Oruka Therapeutics, Inc. (ORKA)

Sandler Laura Lee — Chief Operating Officer
May 1, 2026
Sale
Shares
400
Price
$66.06
Total Value
$26.42K
Shares Held After
237,284
% of Holdings
0.2%

Oruka Therapeutics, Inc. (ORKA)

Sandler Laura Lee — Chief Operating Officer
May 1, 2026
Sale
Shares
300
Price
$65.10
Total Value
$19.53K
Shares Held After
237,684
% of Holdings
0.1%

Oruka Therapeutics, Inc. (ORKA)

Sandler Laura Lee — Chief Operating Officer
May 1, 2026
Sale
Shares
1,800
Price
$64.15
Total Value
$115.47K
Shares Held After
237,984
% of Holdings
0.8%

Oruka Therapeutics, Inc. (ORKA)

Sandler Laura Lee — Chief Operating Officer
May 1, 2026
Sale
Shares
2,200
Price
$62.58
Total Value
$137.69K
Shares Held After
239,784
% of Holdings
0.9%

Contineum Therapeutics, Inc. (CTNM)

Lorrain Daniel S. — Chief Scientific Officer
May 1, 2026
Sale
Shares
300
Price
$13.84
Total Value
$4.15K
Shares Held After
143,542
% of Holdings
0.2%

Contineum Therapeutics, Inc. (CTNM)

Lorrain Daniel S. — Chief Scientific Officer
May 1, 2026
Sale
Shares
3,870
Price
$13.06
Total Value
$50.54K
Shares Held After
143,842
% of Holdings
2.6%

Vaxcyte, Inc. (PCVX)

Wassil Jim — CHIEF OPERATING OFFICER
May 1, 2026
Sale
Shares
2,250
Price
$56.83
Total Value
$127.87K
Shares Held After
160,744
% of Holdings
1.4%

Xeris Biopharma Holdings, Inc. (XERS)

Hecht Beth — Chief Legal Officer and Corporate Secretary
May 1, 2026
Sale
Shares
16,667
Price
$6.23
Total Value
$103.81K
Shares Held After
1,193,173
% of Holdings
1.4%

Nurix Therapeutics, Inc. (NRIX)

Ring Christine — Chief Legal Officer
May 1, 2026
Sale
Shares
5,394
Price
$16.76
Total Value
$90.41K
Shares Held After
26,453
% of Holdings
16.9%
May 1, 2026
Sale
Shares
10,781
Price
$6.47
Total Value
$69.75K
Shares Held After
121,451
% of Holdings
8.2%
Shares
48,565
Price
$54.02
Total Value
$2.62M
Shares Held After
0
% of Holdings
100.0%
Apr 30, 2026
Purchase
Shares
25,000
Price
$1.00
Total Value
$25.00K
Shares Held After
27,046
% of Holdings
92.4%
Apr 30, 2026
Sale
Shares
168,262
Price
$0.72
Total Value
$121.15K
Shares Held After
1,785,687
% of Holdings
8.6%

BridgeBio Pharma, Inc. (BBIO)

Apuli Maricel — Chief Accounting Officer
Apr 30, 2026
Sale
Shares
2,000
Price
$71.58
Total Value
$143.16K
Shares Held After
134,115
% of Holdings
1.5%

Pharvaris N.V. (PHVS)

Lu Peng — Chief Medical Officer
Apr 30, 2026
Sale
Shares
15,000
Price
$30.24
Total Value
$453.63K
Shares Held After
66,083
% of Holdings
18.5%

Pharvaris N.V. (PHVS)

Lesage Anne — Chief Early Development
Apr 30, 2026
Sale
Shares
19,200
Price
$30.26
Total Value
$580.91K
Shares Held After
133,969
% of Holdings
12.5%

Pharvaris N.V. (PHVS)

Lesage Anne — Chief Early Development
Apr 30, 2026
Sale
Shares
18,000
Price
$30.26
Total Value
$544.60K
Shares Held After
56,450
% of Holdings
24.2%

Pharvaris N.V. (PHVS)

Lesage Anne — Chief Early Development
Apr 30, 2026
Sale
Shares
3,700
Price
$30.26
Total Value
$111.95K
Shares Held After
56,450
% of Holdings
6.2%
Shares
670
Price
$31.03
Total Value
$20.79K
Shares Held After
355,167
% of Holdings
0.2%
Shares
28,400
Price
$30.30
Total Value
$860.59K
Shares Held After
355,837
% of Holdings
7.4%

Processa Pharmaceuticals, Inc. (PCSA)

Lin Patrick — Chief Business - Strategy Off
Apr 30, 2026
Purchase
Shares
1,511
Price
$2.69
Total Value
$4.06K
Shares Held After
6,236
% of Holdings
24.2%
Apr 30, 2026
Purchase
Shares
2,034
Price
$2.69
Total Value
$5.47K
Shares Held After
6,013
% of Holdings
33.8%

Processa Pharmaceuticals, Inc. (PCSA)

SKIBSTED RUSSELL — Chief Financial Officer
Apr 30, 2026
Purchase
Shares
2,190
Price
$2.69
Total Value
$5.89K
Shares Held After
6,498
% of Holdings
33.7%

Processa Pharmaceuticals, Inc. (PCSA)

Guy Wendy — Chief Administrative Officer
Apr 30, 2026
Purchase
Shares
1,748
Price
$2.69
Total Value
$4.70K
Shares Held After
6,441
% of Holdings
27.1%

Avalo Therapeutics, Inc. (AVTX)

Sullivan Christopher Ryan — Chief Financial Officer
Apr 30, 2026
Sale
Shares
8,457
Price
$13.23
Total Value
$111.85K
Shares Held After
423
% of Holdings
95.2%
Apr 30, 2026
Purchase
Shares
1,706
Price
$2.69
Total Value
$4.59K
Shares Held After
13,813
% of Holdings
12.4%
Apr 30, 2026
Sale
Shares
40
Price
$579.51
Total Value
$23.18K
Shares Held After
40,513
% of Holdings
0.1%
Apr 30, 2026
Sale
Shares
460
Price
$577.97
Total Value
$265.87K
Shares Held After
40,553
% of Holdings
1.1%
Apr 30, 2026
Sale
Shares
316
Price
$577.10
Total Value
$182.36K
Shares Held After
41,013
% of Holdings
0.8%
Apr 30, 2026
Sale
Shares
424
Price
$576.14
Total Value
$244.28K
Shares Held After
41,329
% of Holdings
1.0%
Apr 30, 2026
Sale
Shares
312
Price
$574.79
Total Value
$179.34K
Shares Held After
41,753
% of Holdings
0.7%
Apr 30, 2026
Sale
Shares
928
Price
$573.85
Total Value
$532.53K
Shares Held After
42,065
% of Holdings
2.2%
Apr 30, 2026
Sale
Shares
1,640
Price
$572.57
Total Value
$939.02K
Shares Held After
42,993
% of Holdings
3.7%
Apr 30, 2026
Sale
Shares
3,826
Price
$571.59
Total Value
$2.19M
Shares Held After
44,633
% of Holdings
7.9%
Apr 30, 2026
Sale
Shares
1,194
Price
$570.76
Total Value
$681.48K
Shares Held After
48,459
% of Holdings
2.4%
Apr 30, 2026
Sale
Shares
360
Price
$569.54
Total Value
$205.03K
Shares Held After
49,653
% of Holdings
0.7%

UNITED THERAPEUTICS Corp (UTHR)

EDGEMOND JAMES — CFO AND TREASURER
Apr 30, 2026
Sale
Shares
40
Price
$578.76
Total Value
$23.15K
Shares Held After
18,876
% of Holdings
0.2%

UNITED THERAPEUTICS Corp (UTHR)

EDGEMOND JAMES — CFO AND TREASURER
Apr 30, 2026
Sale
Shares
378
Price
$578.07
Total Value
$218.51K
Shares Held After
18,916
% of Holdings
2.0%

UNITED THERAPEUTICS Corp (UTHR)

EDGEMOND JAMES — CFO AND TREASURER
Apr 30, 2026
Sale
Shares
336
Price
$577.24
Total Value
$193.95K
Shares Held After
19,294
% of Holdings
1.7%

UNITED THERAPEUTICS Corp (UTHR)

EDGEMOND JAMES — CFO AND TREASURER
Apr 30, 2026
Sale
Shares
486
Price
$576.24
Total Value
$280.05K
Shares Held After
19,630
% of Holdings
2.4%

UNITED THERAPEUTICS Corp (UTHR)

EDGEMOND JAMES — CFO AND TREASURER
Apr 30, 2026
Sale
Shares
273
Price
$574.96
Total Value
$156.97K
Shares Held After
20,116
% of Holdings
1.3%

UNITED THERAPEUTICS Corp (UTHR)

EDGEMOND JAMES — CFO AND TREASURER
Apr 30, 2026
Sale
Shares
887
Price
$574.07
Total Value
$509.20K
Shares Held After
20,389
% of Holdings
4.2%

UNITED THERAPEUTICS Corp (UTHR)

EDGEMOND JAMES — CFO AND TREASURER
Apr 30, 2026
Sale
Shares
880
Price
$573.00
Total Value
$504.24K
Shares Held After
21,276
% of Holdings
4.0%

UNITED THERAPEUTICS Corp (UTHR)

EDGEMOND JAMES — CFO AND TREASURER
Apr 30, 2026
Sale
Shares
3,034
Price
$572.00
Total Value
$1.74M
Shares Held After
22,156
% of Holdings
12.0%

UNITED THERAPEUTICS Corp (UTHR)

EDGEMOND JAMES — CFO AND TREASURER
Apr 30, 2026
Sale
Shares
2,940
Price
$571.23
Total Value
$1.68M
Shares Held After
25,190
% of Holdings
10.5%

UNITED THERAPEUTICS Corp (UTHR)

EDGEMOND JAMES — CFO AND TREASURER
Apr 30, 2026
Sale
Shares
484
Price
$570.19
Total Value
$275.97K
Shares Held After
28,130
% of Holdings
1.7%
Version: v26.5.2